We recently did a blogpost on Chemotherapy-induced nausea and vomiting (CINV), a  common — and often costly — problem among patients with cancer.
Chemotherapy drugs are very powerful and they cause damage to many growing cells, including some healthy cells.
This damage causes the side effects of chemotherapy, which can include Nausea and Vomiting; Diarrhoea; Constipation, and many more.
Cinvanti (aprepitant) injectable emulsion – was recently approved by the Food and Drug Administration (FDA) to treat chemotherapy-induced nausea/vomiting (CINV).

The drug will be used in combination with other antiemetic agents, for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) and repeat courses of moderately emetogenic cancer chemotherapy (MEC).
CINV remains a high unmet medical need in the oncology community, and five full days of CINV coverage continues to be our goal. NK1 receptor antagonists are recommended for routine use with HEC and are a recommended option with MEC. Despite this, NK1 receptor antagonists are underutilized in CINV. This provides a large opportunity for CINVANTI to help more patients avoid CINV and adhere to their chemotherapy regimens,” said Jeffrey F. Patton, M.D., Chief Executive Officer of Tennessee Oncology in a statement.
Cinvanti is the first-approved neurokinin-1 (NK1) receptor antagonist that does not have polysorbate 80, which frequently causes allergic reactions that may make patients unable to take another anti-emetic.
Aprepitant has long been the standard in the NK1 class and it remains the only single-agent NK1 with proven efficacy in preventing CINV in both the acute and delayed phases in HEC and MEC. Because CINVANTI is a novel, polysorbate 80-free IV formulation of aprepitant, it enables physicians to provide patients with standard-of-care efficacy without the potential risk of polysorbate 80-related adverse events, such as infusion-site reactions,” said Rudolph M. Navari, M.D., Ph.D., University of Alabama, Birmingham School of Medicine, Director, Cancer Care Program, Division of Hematology Oncology.
The commercial launch of the drug is planned for January 2018, according to Heron Therapeutics.
CINV is still a major concern for patients with cancer. If patients do not receive proper CINV prophylaxis [prevention], I would estimate that more than half of patients suffer from CINV. With the proper CINV prophylaxis, it is about 25% of patients who still have persistent symptoms of nausea and vomiting, especially in the breast cancer patient population,” according to Eric Roeland, M.D., author, medical oncologist and palliative care specialist at University of California San Diego Health.
Roeland hopes that research will continue to advance in the field of CINV, particularly in assessing who is at a higher risk for the effect, as well as implementing and standardising treatment protocols that can take people from having less nausea and vomiting to having none at all.

Leave a Comment

%d bloggers like this: